Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022098809 - DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1

Publication Number WO/2022/098809
Publication Date 12.05.2022
International Application No. PCT/US2021/057971
International Filing Date 04.11.2021
IPC
A61K 31/506 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
C07D 239/02 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
C07D 239/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
06having one double bond between ring members or between a ring member and a non-ring member
08with hetero atoms directly attached in position 2
12Nitrogen atoms not forming part of a nitro radical
C07D 239/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
06having one double bond between ring members or between a ring member and a non-ring member
08with hetero atoms directly attached in position 2
12Nitrogen atoms not forming part of a nitro radical
14with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
CPC
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 239/49
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
48Two nitrogen atoms
49with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Applicants
  • MERCK SHARP & DOHME LLC [US]/[US]
  • ACHAB, Abdelghani [US]/[US] (US)
  • CANDITO, David A. [CA]/[US] (US)
  • DONOFRIO, Anthony [US]/[US] (US)
  • FRADERA, Xavier [ES]/[US] (US)
  • KAWAMURA, Shuhei [JP]/[US] (US)
  • LEVI, Samuel M. [US]/[US] (US)
  • LI, Bing [US]/[US] (US)
  • NAIR, Anilkumar G. [US]/[US] (US)
  • PASTERNAK, Alexander [US]/[US] (US)
  • VARA, Brandon A. [US]/[US] (US)
  • YU, Elsie C. [US]/[US] (US)
Inventors
  • ACHAB, Abdelghani
  • CANDITO, David A.
  • DONOFRIO, Anthony
  • FRADERA, Xavier
  • KAWAMURA, Shuhei
  • LEVI, Samuel M.
  • LI, Bing
  • NAIR, Anilkumar G.
  • PASTERNAK, Alexander
  • VARA, Brandon A.
  • YU, Elsie C.
Common Representative
  • MERCK SHARP & DOHME LLC
Priority Data
63/111,38909.11.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1
(FR) INHIBITEURS DE DIAMINOPYRIMIDINE CARBOXAMIDE DE HPK1
Abstract
(EN) Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
(FR) L'invention concerne des composés de formule I : ou des sels pharmaceutiquement acceptables correspondants qui sont des inhibiteurs de la kinase-1 hématopoïétique progénitrice (HPK1) utiles dans le traitement de maladies ou de troubles associés à HPK1. Des utilisations de ces composés dans le traitement potentiel ou la prévention potentielle d'une maladie ou d'un trouble associé à HPK-1 sont également divulguées. Des compositions comprenant un ou plusieurs des composés sont également divulguées. Des utilisations de ces compositions dans le traitement ou la prévention potentiels d'une maladie ou d'un trouble associé à HPK1 sont en outre divulguées.
Latest bibliographic data on file with the International Bureau